Current status of antivascular therapy and targeted treatment in the clinic

International Journal of Hyperthermia

Volumn 24, Issue 1, 2008, Pages 97-110

  Dahl, Olav ^a,b   Borkamo, Erling Dahl ^a   Fluge, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Clinical studies antivascular drugs; Hyperthermia

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR 2;

ACNE; ADJUVANT THERAPY; ASTHENIA; B CELL LYMPHOMA; BLEEDING; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FATIGUE; FISTULA; GASTROINTESTINAL STROMAL TUMOR; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTHERMIC THERAPY; HYPOMAGNESEMIA; KIDNEY CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; PANCREAS CANCER; PROTEINURIA; SKIN TOXICITY; SOMNOLENCE; SURVIVAL TIME; THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 38849099096     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701824406     Document Type: Conference Paper

References (200)

1. Folkman, J. (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med, 285, pp. 1182-1186.
2. Folkman, J. (1972) Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg, 175, pp. 409-416.
3. Folkman, J. (1974) Proceedings: Tumor angiogenesis factor. Cancer Res. 34, pp. 2109-2113.
4. Folkman, J. (2007) Angiogenesis: An organizing principle for drug discovery?. Nat Rev Drug Discov, 6, pp. 273-286.
5. Hanahan, D. and Weinberg, RA (2000) The hallmarks of cancer. Cell, 100, pp. 57-70.
6. Minchinton, AI and Tannock, IF (2006) Drug penetration in solid tumours. Nat Rev Cancer, 6, pp. 583-592.
7. Harris, M. (2004) Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol, 5, pp. 292-302.
8. Imai, K. and Takaoka, A. (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer, 6, pp. 714-727.
9. Druker, BJ, Talpaz, M., Resta, DJ, Peng, B., Buchdunger, E., Ford, JM, Lydon, NB, Kantarjian, H., Capdeville, R. and Ohno-Jones, S. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344, pp. 1031-1037.
10. Schiffer, CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med, 357, pp. 258-265.
11. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, NB, Gilliland, DG and Druker, BJ (1997) CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90, pp. 4947-4952.
12. Druker, BJ and Lydon, NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 105, pp. 3-7.
13. Goldman, JM and Melo, JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344, pp. 1084-1086.
14. Coutre, P le, Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F. and Gambacorti-Passerini, C. (1999) In vivo eradication of human BCR/ABLpositive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst, 91, pp. 163-168.
15. Schindler, T., Bornmann, W., Pellicena, P., Miller, WT, Clarkson, B. and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, pp. 1938-1942.
16. Thiesing, JT, Ohno-Jones, S., Kolibaba, KS and Druker, BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcrabl-positive cells. Blood, 96, pp. 3195-3199.
17. Vigneri, P. and Wang, JY (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med, 7, pp. 228-2234.
18. Joensuu, H., Roberts, PJ, Sarlomo-Rikala, M., Andersson, LC, Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S. and Druker, B. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 344, pp. 1052-1056.
19. Verweij, J., Casali, PG, Zalcberg, J., LeCesne, A., Reichardt, P., Blay, JTY, Issels, R., van Oosterom, A., Hogendoorn, PC and Van Glabbeke, M. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet, 364, pp. 1127-1134.
20. Shimizu, A., O'Brien, KP, Sjoblom, T., Pietras, K., Buchdunger, E., Collins, VP, Heldin, CH, Dumanski, JP and Ostman, A. (1999) The dermatofibrosarcoma protuberans associated collagen type Ialpha1/ platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res, 59, pp. 3719-3723.
21. McArthur, G. (2007) Dermatofibrosarcoma protuberans: Recent clinical progress. Ann Surg Oncol, 14, pp. 2876-2886.
22. Curtis, CE, Grand, FH, Musto, P., Clark, A., Murphy, J., Minervini, MM Perla G., Stewart, J., Reiter, A. and Cross, NC (2007) Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol, 138, pp. 77-81.
23. Fletcher, S. and Bain, B. (2007) Eosinophilic leukaemia. Br Med Bull, 8182, pp. 115-127.
24. Gotlib, J., Cools, J., Malone III, JM, Schrier, SL, Gilliland, DG and Coutre, SE (2004) The FIP1L1- PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management. Blood, 103, pp. 2879-2891.
25. Kalac, M., Quintas-Cardama, A., Vrhovac, R., Kantarjian, H. and Verstovsek, S. (2007) A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer, 110, pp. 955-964.
26. Pardanani, A., Reeder, T., Porrata, LF, Li, CY, Tazelaar, HD, Baxter, EJ, Witzig, TE, Cross, NC and Tefferi, A. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood, 101, pp. 3391-3397.
27. Jovanovic, JV, Score, J., Waghorn, K., Cilloni, D., Gottardi, E., Metzgeroth, G., Erben, P., Popp, H., Walz, C. and Hochhaus, A. (2007) Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood, 109, pp. 4635-4640.
28. Krause, DS and Van Etten, RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353, pp. 172-187.
29. Guilhot, F., Apperley, J., Kim, DW, Bullorsky, EO, Baccarani, M., Roboz, GJ, Amadori, S., de Souza, CA, Lipton, JH and Hochhaus, A. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in accelerated phase. Blood, 109, pp. 4143-4150.
30. Cheson, BD (2002) CHOP plus rituximab - Balancing facts and opinion. N Engl J Med, 346, pp. 280-282.
31. Coiffier, B. (2007) Rituximab therapy in malignant lymphoma. Oncogene, 26, pp. 3603-3613.
32. Stephenson, J. (2001) Researchers optimistic about sea change in cancer treatment. JAMA, 285, pp. 2841-2842.
33. Carmeliet, P. and Jain, RK (2000) Angiogenesis in cancer and other diseases. Nature, 407, pp. 249-257.
34. Dvorak, HF (2002) Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol, 20, pp. 4368-4380.
35. Adams, RH and Alitalo, K. (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol, 8, pp. 464-478.
36. Alitalo, K., Tammela, T. and Petrova, TV (2005) Lymphangiogenesis in development and human disease. Nature, 438, pp. 946-953.
37. Ferrara, N., Hillan, KJ, Gerber, HP and Novotny, W. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, pp. 391-400.
38. Kabbinavar, F., Hurwitz, HI, Fehrenbacher, L., Meropol, NJ, Novotny, WF, Lieberman, G., Griffing, S. and Bergsland, E. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol, 21, pp. 60-65.
39. Kabbinavar, FF, Hambleton, J., Mass, RD, Hurwitz, HI, Bergsland, E. and Sarkar, S. (2005) Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol, 23, pp. 3706-3712.
40. Kabbinavar, FF, Schulz, J., McCleod, M., Patel, T., Hamm, JT, Hecht, JR, Mass, R., Perrou, B., Nelson, B. and Novotny, WF (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol, 23, pp. 3697-3705.
41. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S. and Holmgren, E. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, pp. 2335-2342.
42. Giantonio, BJ, Catalano, PJ, Meropol, NJ, O'Dwyer, PJ, Mitchell, EP, Alberts, SR, Schwartz, MA and Benson, AB 3rd (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, pp. 1539-1544.
43. Goldberg, RM (2006) Therapy for metastatic colorectal cancer. Oncologist, 11, pp. 981-987.
44. Grothey, A., Sargent, D., Goldberg, RM and Schmoll, HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22, pp. 209-1214.
45. Meyerhardt, JA and Mayer, RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med, 352, pp. 476-487.
46. Drevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J. and Jurgensmeier, JM (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol, 25, pp. 3045-3054.
47. McDonald, DM and Choyke, PL (2003) Imaging of angiogenesis: From microscope to clinic. Nat Med, 9, pp. 713-725.
48. Miller, JC, Pien, HH, Sahani, D., Sorensen, AG and Thrall, JH (2005) Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst, 97, pp. 172-187.
49. Willett, CG, Boucher, Y., Tomaso, E di, Duda, DG, Munn, LL, Tong, RT, Chung, DC, Sahani, DV, Kalva, SP and Kozin, SV (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, pp. 145-147.
50. Willett, CG, Duda, DG, Tomaso, E di, Boucher, Y., Czito, BG, Vujaskovic, Z., Vlahovic, G., Bendell, J., Cohen, KS and Hurwitz, HI (2007) Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol, 4, pp. 316-321.
51. Sandler, A. (2007) Bevacizumab in non small cell lung cancer. Clin Cancer Res, 13, pp. 4613s-4616s.
52. Cohen, MH, Gootenberg, J., Keegan, P. and Pazdur, R. (2007) FDA drug approval summary: Bevacizumab (avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non small cell lung cancer. Oncologist, 12, pp. 713-718.
53. Stinchcombe, TE and Socinski, MA (2007) Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene, 26, pp. 3691-3698.
54. Cabebe, E. and Wakelee, H. (2007) Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol, 8, pp. 15-27.
55. Junior, G de Castro, Puglisi, F., de Azambuja, E., Saghir, NS El and Awada, A. (2006) Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the 'do ut des' paradigm). Crit Rev Oncol Hematol, 59, pp. 40-50.
56. Los, M., Roodhart, JM and Voest, EE (2007) Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist, 12, pp. 443-450.
57. Arroyo, JG (2006) A 76-year-old man with macular degeneration. JAMA, 295, pp. 2394-2406.
58. Steinbrook, R. (2006) The price of sight-Ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med, 355, pp. 1409-1412.
59. Stone, EM (2006) A very effective treatment for neovascular macular degeneration. N Engl J Med, 355, pp. 1493-1495.
60. (2006) Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM.2 Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol, 142, pp. 1054-1056.
61. Melchert, M. and List, A. (2007) The thalidomide saga. Int J Biochem. Cell Biol, 39, pp. 1489-1499.
62. Morgan, GJ, Krishnan, B., Jenner, M. and Davies, FE (2006) Advances in oral therapy for multiple myeloma. Lancet Oncol, 7, pp. 316-325.
63. Zervas, K., Mihou, D., Katodritou, E., Pouli, A., Mitsouli, Ch, Anagnostopoulcs, A., Delibasi, S., Kyrtsonis, M., Anagnostopoulos, N. and Terpos, E. (2007) VAD-doxil vs. VAD-doxil plus thalidomide as initial treatment for multiple myeloma: Results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol, 18, pp. 1369-1375.
64. Sridhar, SS, Seymour, L. and Shepherd, FA (2003) Inhibitors of epidermal-growth-factor receptors: A review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol, 4, pp. 397-406.
65. Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, GD and Maity, A. (2006) EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res, 66, pp. 3197-3204.
66. Nahta, R. and Esteva, FJ (2007) Trastuzumab: Triumphs and tribulations. Oncogene, 26, pp. 3637-3643.
67. Cobleigh, MA, Vogel, CL, Tripathy, D., Robert, NJ, Scholl, S., Fehrenbacher, L., Wolter, JM, Paton, V., Shak, S. and Lieberman, G. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 17, pp. 2639-2648.
68. Vogel, CL, Cobleigh, MA, Tripathy, D., Gutheil, JC, Harris, LN, Fehrenbacher, L., Slamon, DJ, Murphy, M., Novotny, WF and Burchmore, M. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol, 20, pp. 719-726.
69. Slamon, DJ, Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J. and Pegram, M. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, pp. 783-792.
70. Romond, EH, Perez, EA, Bryant, J., Suman, VJ, CE, Jr Geyer, Davidson, NE, Tan-Chiu, E., Martino, S., Paik, S. and Kaufman, PA (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, pp. 1673-1684.
71. Piccart-Gebhart, MJ, Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R. and Jackisch, C. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, pp. 1659-1672.
72. Baselga, J., Perez, EA, Pienkowski, T. and Bell, R. (2006) Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11, pp. 4-12.
73. Pritchard, Kl, Shepherd, LE, O'Malley, FP, Andrulis, IL, Tu, D., Bramwell, VH and Levine, MN (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med, 354:20, pp. 2103-2111.
74. Smith, I., Procter, M., Gelber, RD, Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G. and Baselga, J. (2007) Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet, 369, pp. 29-36.
75. Engel, RH and Kaklamani, VG (2007) HER2-positive breast cancer: Current and future treatment strategies. Drugs, 67, pp. 1329-1341.
76. Geyer, CE, Forster, J., Lindquist, D., Chan, S., Romieu, CG, Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A. and Kaufman, B. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355, pp. 2733-2743.
77. Kris, MG, Natale, RB, Herbst, RS, TJ, Jr Lynch, Prager, D., Belanj, CP, Schiller, JH, Kelly, K., Spiridonidis, H. and Sandler, A. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: A randomized trial. JAMA, 290, pp. 2149-2158.
78. Giaccone, G. (2004) The role of gefitinib in lung cancer treatment. Clin Cancer Res, 10, pp. 4233s-4237s.
79. Bell, DW, Lynch, TJ, Haserlat, SM, Harris, PL, Okimoto, RA, Brannigan, BW, Sgroi, DC, Muir, B., Riemenschneider, MJ and Lacona, RB (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol, 23, pp. 8081-8092.
80. Shepherd, FA, Pereira, J Rodrigues, Ciuleanu, T., Tan, EH, Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M. and Martins, R. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, pp. 123-132.
81. Sharma, SV, Bell, DW, Settleman, J. and Haber, DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer, 7, pp. 169-181.
82. Gatzemeier, U., Pluzanska, A., Szczesna, A., Kaukel, E., Roubec, J., De Rosa, F., Milanowski, J., Karnicka-Mlodkowski, H., Pesek, M. and Serwatowski, P. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 25, pp. 1545-1552.
83. Karamouzis, MV, Grandis, JR and Argiris, A. (2007) Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA, 298, pp. 70-82.
84. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A. and Verslype, C. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351, pp. 337-345.
85. Saltz, LB, Meropol, NJ, Loehrer, PJ, Needle, MN, Kopit, J. and Mayer, RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22, pp. 1201-1208.
86. Lenz, HJ, Van Cutsem, E., Khambata-Ford, S., Mayer, RJ, Gold, P., Stella, P., Mirtsching, B., Cohn, AL, Pippas, AW and Azarnia, N. (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol, 24, pp. 4914-4921.
87. Chung, KY, Shia, J., Kemeny, NE, Shah, M., Schwartz, GK, Tse, A., Hamilton, A., Pan, D., Schrag, D. and Schwartz, L. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23, pp. 1803-1810.
88. Khambata-Ford, S., Garrett, CR, Meropol, NJ, Basik, M., Harbison, CT, Wu, S., Wong, TW, Huang, X., Takimoto, CH and Godwin, AK (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol, 25, pp. 3230-3237.
89. Galizia, G., Lieto, E., De Vita, M., Orditura, F., Castellano, P., Troiani, T., Imperatore, V. and Ciardiello, F. (2007) Cetuximab, a chimeric human mouse antiepidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, 26, pp. 3654-3660.
90. Hildebrandt, B., Coutre, P le, Nicolaou, A., Koble, K., Riess, H. and Dorken, B. (2007) Cetuximab: Appraisal of a novel drug against colorectal cancer. Recent Results Cancer Res, 176, pp. 135-143.
91. Van Cutsem, E., Peeters, M. and Siena, S. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol, 25, pp. 1658-1664.
92. Lievre, A., Bachet, JB, Corre, D Le, Boige, V., Landi, B., Côte, JF Emile JF, Tomasic, G., Penna, C. and Ducreux, M. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66, pp. 3992-3995.
93. Benvenuti, S., Sartore-Bianchi, A., Nicolantonio, F Di, Zanon, C., Moroni, M., Veronese, S., Siena, S. and Bardelli, A. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 67, pp. 2643-2648.
94. Fiore, F Di, Blanchard, F., Charbonnier, F., Pessot, F Le, Lamy, A., Galais, MP, Bastit, L., Killian, A., SesboSesboüé, R. and Tuech, JJ (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer, 96, pp. 1166-1169.
95. Moore, MJ, Goldstein, D., Hamm, J., Figer, A., Hecht, JR, Gallinger, S., Au, HJ, Murawa, P., Walde, D. and Wolff, RA (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25, pp. 1960-1966.
96. Pugh, CW and Ratcliffe, PJ (2003) Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med, 9, pp. 677-684.
97. Cohen, HT and McGovern, FJ (2005) Renal-cell carcinoma. N Engl J Med, 353:23, pp. 2477-2490.
98. Rini, BI and Small, EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol, 23, pp. 1028-1043.
99. Brugarolas, J. (2007) Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med, 356, pp. 185-187.
100. Yang, JC, Haworth, L., Sherry, RM, Hwu, P., Schwartzentruber, DJ, Topalian, SL, Steinberg, SM, Chen, HX and Rosenberg, SA (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349, pp. 427-434.
101. Motzer, RJ, Rini, BI, Bukowski, RM, Curti, BD, George, DJ, Hudes, GR, Redman, BG, Margolin, KA, Merchan, JR and Wilding, G. (2006) Sunitinib in patients with metastatic renal cell carcinoma. 2. Jama, 295, pp. 2516-2524.
102. Motzer, RJ, Hutson, TE, Tomczak, P., Michaelson, MD, Bukowski, RM, Rixe, O., Oudard, S., Negrier, S., Szczylik, C. and Kim, ST (2007) Sunitinib vs. interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356, pp. 115-124.
103. Hainsworth, JD, Sosman, JA, Spigel, DR, Edwards, DL, Baughman, C. and Greco, A. (2005) Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol, 23, pp. 7889-7896.
104. Ratain, MJ, Eisen, T., Stadler, WM, Flaherty, KT, Kaye, SB, Rosner, GL, Gore, M., Desai, AA, Patnaik, A. and Xiong, HQ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 24, pp. 2505-2512.
105. Escudier, B., Eisen, T., Stadler, WM, Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E. and Desai, AA (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 356, pp. 125-134.
106. Raffetto, JD and Khalil, RA (2007) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol, p. 7.
107. Gasparini, G., Longo, R., Toi, M. and Ferrara, N. (2005) Angiogenic inhibitors: A new therapeutic strategy in oncology. Nat Clin Pract Oncol, 2, pp. 562-577.
108. Hidalgo, M. and Eckhardt, SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst, 93, pp. 178-193.
109. Thorpe, PE (2004) Vascular targeting agents as cancer therapeutics. Clin. Cancer Res, 10, pp. 415-427.
110. Siemann, DW, Chaplin, DJ and Horsman, MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer, 100, pp. 2491-2499.
111. Patterson, DM and Rustin, GJ (2007) Vascular damaging agents. Clin Oncol (R Coll Radiol), 19, pp. 443-456.
112. Denekamp, J., Hill, SA and Hobson, B. (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol, 19, pp. 271-275.
113. Denekamp, J. (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol, 23, pp. 217-225.
114. Hill, SA, Lonergan, SJ, Denekamp, J. and Chaplin, DJ (1993) Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer, 29:9, pp. 1320-1324.
115. Eikesdal, HP, Bjerkvig, R. and Dahl, O. (2001) Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: Therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys, 51, pp. 535-544.
116. Eikesdal, HP, Bjerkvig, R., Mella, O. and Dahl, O. (2001) Combretastatin A-4 and hyperthermia: A potent combination for the treatment of solid tumors. Radiother Oncol, 60, pp. 147-154.
117. Vincent, L., Kermani, P., Young, LM, Cheng, J., Zhang, F., Shido, K., Lam, G., Bompais-Vincent, H., Zhu, Z. and Hicklin, DJ (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest, 115, pp. 2992-3006.
118. Salmon, BA and Siemann, DW (2007) Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys, 68, pp. 211-217.
119. Griffin, RJ, Monzen, H., Williams, BW, Park, H., Lee, SH and Song, CW (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia, 19, pp. 575-589.
120. Murata, R. and Horsman, MR (2004) Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia, 20, pp. 393-404.
121. Hagen, TL ten and Eggermont, AM (2006) Changing the pathophysiology of solid tumours: The potential of TNF and other vasoactive agents. Int J Hyperthermia, 22, pp. 241-246.
122. Horsman, MR (2006) Tissue physiology and the response to heat. Int J Hyperthermia, 22, pp. 197-203.
123. Brunstein, F., Rens, J., van Tiel, ST, Eggermont, AM and Hagen, TL ten (2006) Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery. Br J Cancer, 95, pp. 1663-1669.
124. Thorpe, PE, Chaplin, DJ and Blakey, DC (2003) The first international conference on vascular targeting: Meeting overview. Cancer Res, 63, pp. 1144-1147.
125. Albertsson, P., Lennernas, B. and Norrby, K. (2006) On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGE-A. Acta Oncol, 45, pp. 144-155.
126. Bocci, G., Tuccori, M., Emmenegger, U., Liguori, V., Falcone, A., Kerbel, RS and Tacca, M Del (2005) Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann Oncol, 16, pp. 1243-1252.
127. Damber, JE, Vallbo, C., Albertsson, P., Lennernas, B. and Norrby, K. (2006) The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol, 58, pp. 354-360.
128. Gasparini, G. (2001) Metronomic scheduling: The future of chemotherapy?. Lancet Oncol, 2, pp. 733-740.
129. Kerbel, RS (2006) Antiangiogenic therapy: A universal chemosensitization strategy for cancer?. Science, 312, pp. 1171-1175.
130. Browder, T., Butterfield, CE, Kraling, BM, Shi, B., Marshall, B., O'Reilly, MS and Folkman, J. (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res, 60, pp. 1878-1886.
131. Broxterman, HJ, Lankelma, J. and Hoekman, K. (2003) Resistance to cytotoxic and anti-angiogenic anticancer agents: Similarities and differences. Drug Resist Updat, 6, pp. 111-127.
132. Kamat, AA, Kim, TJ, Landen Jr, CN, Lu, C., Han, LY, Lin, YG, Merritt, WM, Thaker, PH, Gershenson, DM and Bischoff, F. (2007) Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res, 67, pp. 281-288.
133. Folkins, C., Man, S., Xu, P., Shaked, Y., Hicklin, DJ and Kerbel, RS (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res, 67, pp. 3560-3564.
134. Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y. and Kerbel, RS (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res, 63, pp. 4342-4346.
135. Bertolini, F., Shaked, Y., Mancuso, P. and Kerbel, RS (2006) The multifaceted circulating endothelial cell in cancer: Towards marker and target identification. Nat Rev Cancer, 6, p. 835.
136. Rafii, S., Lyden, D., Benezra, R., Hattori, K. and Heissig, B. (2002) Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. Nat Rev Cancer, 2, pp. 826-835.
137. Jubb, AM, Oates, AJ, Holden, S. and Koeppen, H. (2006) Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer, 6, pp. 626-635.
138. Dewhirst, MW, Vujaskovic, Z., Jones, E. and Thrall, D. (2005) Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia, 21, pp. 779-790.
139. Kampinga, HH (2006) Cell biological effects of hyperthermia alone or combined with radiation or drugs: A short introduction to newcomers in the field. Int J Hyperthermia, 22, pp. 191-196.
140. Wust, P., Hildebrandt, B., Sreenivasa, G., Rau, B., Gellermann, J., Riess, H., Felix, R. and Schlag, PM (2002) Hyperthermia in combined treatment of cancer. Lancet Oncol, 3, pp. 487-497.
141. Dahl, O. and Overgaard, J. (2002) Hyperthermia. Oxford Textbook of oncology., 1, pp. 511-525. Oxford University Press, Oxford
142. Jackson, IL, Batinic-Haberle, I., Sonveaux, P., Dewhirst, MW and Vujaskovic, Z. (2006) ROS production and angiogenic regulation by macrophages in response to heat therapy. Int J Hyperthermia, 22, pp. 263-273.
143. Lyng, H., Monge, OR, Bohler, PJ and Rofstad, EK (1991) Relationships between thermal dose and heat-induced tissue and vascular damage after thermoradiotherapy of locally advanced breast carcinoma. Int J Hyperthermia, 7, pp. 403-415.
144. Rofstad, EK and Brustad, T. (1981) Response of human malignant melanoma xenografts to hyperthermia: Effect of vascular occlusion. Int J Radiat Oncol Biol Phys, 7, pp. 1685-1687.
145. Thrall, DE, Larue, SM, Pruitt, AF, Case, B. and Dewhirst, MW (2006) Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia, 22, pp. 365-373.
146. Song, CW, Park, HJ, Lee, CK and Griffin, R. (2005) Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia, 21, pp. 761-767.
147. Fajardo, LF and Prionas, SD (1994) Endothelial cells and hyperthermia. Int J Hyperthermia, 10, pp. 347-353.
148. Fajardo, LF, Prionas, SD, Kowalski, J. and Kwan, HH (1988) Hyperthermia inhibits angiogenesis. Radiat Res, 114, pp. 297-306.
149. Eikesdal, HP, Bjorkhaug, ST and Dahl, O. (2002) Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: Lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia, 18, p. 141.
150. Kanamori, S., Nishimura, Y., Okuno, Y., Horii, N., Saga, T. and Hiraoka, M. (1999) Induction of vascular endothelial growth factor (VEGF) by hyperthermia and/or an angiogenesis inhibitor. Int J Hyperthermia, 15, pp. 267-278.
151. Sawaji, Y., Sato, T., Takeuchi, A., Hirata, M. and Ito, A. (2002) Anti-angiogenic action of hyperthermia by suppressing gene expression and production of tumour-derived vascular endothelial growth factor in vivo and in vitro. Br J Cancer, 86, p. 1597.
152. Srinivasan, JM, Fajardo, LF and Hahn, GM (1990) Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor. J Natl Cancer Inst, 82, pp. 1904-1910.
153. Valdagni, R. and Amichetti, M. (1994) Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys, 28, pp. 163-169.
154. Overgaard, J., Gonzalez, D Gonzalez, Hulshof, MC, Arcangeli, G., Dahl, O., Mella, O. and Bentzen, SM (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet, 345, pp. 540-543.
155. Overgaard, J., Gonzalez, D Gonzalez, Hulshof, MC, Arcangeli, G., Dahl, O., Mella, O. and Bentzen, SM (1996) Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia, 12, pp. 3-20.
156. Hand, JW, Machin, D., Vernon, CC and Whaley, JB (1997) Analysis of thermal parameters obtained during phase III trials of hyperthermia as an adjunct to radiotherapy in the treatment of breast carcinoma. Int J Hyperthermia, 13, pp. 343-364.
157. Vernon, CC, Hand, JW, Field, SB, Machin, D., Whaley, JB, van der Zee, J., van Putten, WL, van Rhoon, GC, van Dijk, JD and Gonzalez, D Gonzalez (1996) Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys, 35, pp. 731-744.
158. Prosnitz, LR, Maguire, P., Anderson, JM, Scully, SP, Harrelson, JM, Jones, EL, Dewhirst, M., Samulski, TV, Powers, BE and Rosner, GL (1999) The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys, 45, pp. 941-949.
159. Maguire, PD, Samulski, TV, Prosnitz, LR, Jones, EL, Rosner, GL, Powers, B., Layfield, LW, Brizel, DM, Scully, SP and Harrelson, JM (2001) A phase II trial testing the thermal dose parameter CEM43 degrees T90 as a predictor of response in soft tissue sarcomas treated with pre-operative thermoradiotherapy. Int J Hyperthermia, 17, pp. 283-290.
160. Issels, RD (2006) High-risk soft tissue sarcoma: Clinical trial and hyperthermia combined chemotherapy. Int J Hyperthermia, 22, pp. 235-239.
161. Sneed, PK, Stauffer, PR, McDermott, MW, Diederich, CJ, Lamborn, KR, Prados, MD, Chang, S., Weaver, KA, Spry, L. and Malec, MK (1998)
162. van der Zee, J., Gonzalez, D Gonzalez, van Rhoon, GC, van Dijk, JD, van Putten, WL and Hart, AA (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet, 355, pp. 1119-1125.
163. van der Zee, J. and van Rhoon, GC (2006) Cervical cancer: Radiotherapy and hyperthermia. Int J Hyperthermia, 22, pp. 229-234.
164. Harima, Y., Nagata, K., Harima, K., Ostapenko, VV, Tanaka, Y. and Sawada, S. (2001) A randomized clinical trial of radiation therapy vs. thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia, 17, pp. 97-105.
165. Westermann, AM, Jones, EL, Schem, BC, van der Steen-Banasik, EM, Koper, P., Mella, O., Uitterhoeve, AL, de Wit, R., van der Velden, J. and Burger, C. (2005) First results of triple-modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with stage IIB, III, and IVA cervical carcinoma. Cancer, 104, pp. 763-770.
166. Colombo, R., Da Pozzo, LF, Salonia, A., Rigatti, P., Leib, Z., Baniel, J., Caldarera, E. and Pavone-Macaluso, M. (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol, 21, pp. 4270-4276.
167. Issels, RD, Lindner, LH, Wust, P., Hohenberger, P., Jauch, K., Daugaard, S., Mannsmann, U., Hiddemann, W., Blay, J. and Verweij, J. (2007) Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised pros. J Clin Oncol, 10009, p. 18s.
168. Secord, A Alvarez, Jones, EL, Hahn, CA, Petros, WP, Yu, D., Havrilesky, LJ, Soper, JT, Berchuck, A., Spasojevic, I. and Clarke-Pearson, DL (2005) Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer. Int J Hyperthermia, 21, pp. 333-347.
169. Johannsen, M., Gnevckow, U., Taymoorian, K., Thiesen, B., Waldöfner, N., Scholz, R., Jung, K., Jordan, A., Wust, P. and Loening, SA (2007) Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial. Int J Hyperthermia, 23, pp. 315-323.
170. Liu, P., Zhang, A., Xu, Y. and Xu, LX (2005) Study of non-uniform nanoparticle liposome extravasation in tumour. Int J Hyperthermia, 21, pp. 259-270.
171. Ponce, AM, Viglianti, BL, Yu, D., Yarmolenko, PS, Michelich, CR, Woo, J., Bally, MB and Dewhirst, MW (2007) Magnetic resonance imaging of temperaturesensitive liposome release: Drug dose painting and antitumor effects. J Natl Cancer Inst, 99, pp. 53-63.
172. Ponce, AM, Vujaskovic, Z., Yuan, F., Needham, D. and Dewhirst, MW (2006) Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia, 22, pp. 205-213.
173. Wust, P., Gneveckow, U., Johannsen, M., Böhmer, D., Henkel, T., Kohmann, F., Sehouli, J., Felix, R., Ricke, J. and Jordan, A. (2006) Magnetic nanoparticles for interstitial thermotherapy-feasibility, tolerance and achieved temperatures. Int J Hyperthermia, 22, pp. 673-685.
174. Siddiqui, F., Ehrhart, EJ, Charles, B., Chubb, L., Li, CY, Zhang, X., Lame, SM, Avery, PR, Dewhirst, MW and Ullrich, RL (2006) Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. Int J Hyperthermia, 22, pp. 587-606.
175. Siddiqui, F., Li, CY, Zhang, X., Larue, SM, Dewhirst, MW, Ullrich, RL and Avery, PR (2006) Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced genetherapy. Int J Hyperthermia, 22, pp. 117-134.
176. Zhang, S., Xu, G., Liu, C., Xiao, S., Sun, Y., Su, X., Cai, Y., Li, D. and Xu, B. (2005) Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia, 21, pp. 631-636.
177. Li, GC, He, F. and Ling, CC (2006) Hyperthermia and gene therapy: Potential use of microPET imaging. Int J Hyperthermia, 22, pp. 215-221.
178. Branford, S., Hughes, T., Milner, A., Koelmeyer, R., Schwarer, A., Arthur, C., Filshie, R., Moreton, S., Lynch, K. and Taylor, K. (2007) Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha. Cancer, 110, pp. 801-808.
179. Epstein, SE, Kornowski, R., Fuchs, S. and Dvorak, HF (2001) Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation, 104, pp. 115-119.
180. Van Glabbeke, M., Verweij, J., Casali, PG, Simes, J., Cesne, A Le, Reichardt, P., Issels, R., Judson, IR, van Oosterom, AT and Blay, JY (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer, 42, pp. 2277-2285.
181. Verheul, HM and Pinedo, HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer, 7, pp. 475-485.
182. Lacouture, ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer, 6, pp. 803-812.
183. Chien, KR (2006) Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med, 354, pp. 789-790.
184. Force, T., Krause, DS and Van Etten, RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer, 7, pp. 332-344.
185. Suter, TM, Procter, M., van Veldhuisen, DJ, Muscholl, M., Bergh, J., Carlomagno, C., Perren, T., Passalacqua, R., Bighin, C. and Klijn, JG (2007) Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. J Clin Oncol, 25, pp. 3859-3865.
186. Scappaticci, FA, Fehrenbacher, L., Cartwright, T., Hainsworth, JD, Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S. and Hurwitz, H. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol, 91, pp. 173-180.
187. Scappaticci, FA, Skillings, JR, Holden, SN, Gerber, HP, Miller, K., Kabbinavar, F., Bergsland, E., Ngai, J., Holmgren, E. and Wang, J. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99, pp. 1232-1239.
188. van Heeckeren, WJ, Ortiz, J., Cooney, MM and Remick, SC (2007) Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker?. J Clin Oncol, 25, pp. 2993-2995.
189. Schulze, T., Wust, P., Gellermann, J., Hildebrandt, B., Riess, H., Felix, R. and Rau, B. (2006) Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. Int J Hyperthermia, 22, pp. 301-318.
190. Haveman, J., Van Der Zee, J., Wondergem, J., Hoogeveen, JF and Hulshof, MC (2004) Effects of hyperthermia on the peripheral nervous system: A review. Int J Hyperthermia, 20, pp. 371-391.
191. Wiggenraad, R., Koning, C., Westermann, C., Jansen, C. and van der Zee, J. (2005) Two cases of fatal necrosis of the lesser pelvis in patients treated with combined radiotherapy and hyperthermia for cervical carcinoma. Int J Hyperthermia, 21, pp. 185-192.
192. Balzer, S., Schneider, DT, Bernbeck, MB, Jager, M., Mils, O., Schaper, J., Willers, R., Krauspe, R., Gobel, U. and Wessalowski, R. (2006) Avascular osteonecrosis after hyperthermia in children and adolescents with pelvic malignancies: A retrospective analysis of potential risk factors. Int J Hyperthermia, 22, pp. 451-461.
193. Gellermann, J., Hildebrandt, B., Issels, R., Ganter, H., Wlodarczyk, W., Budach, V., Felix, R., Tunn, PU, Reichardt, P. and Wust, P. (2006) Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: Correlation with response and direct thermometry. Cancer, 107, pp. 1373-1382.
194. Gellermann, J., Wlodarczyk, W., Feussner, A., Fahling, H., Nadobny, J., Hildebrandt, B., Felix, R. and Wust, P. (2005) Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system. Int J Hyperthermia, 21, pp. 497-513.
195. Hornsleth, SN, Frydendal, L., Mella, O., Dahl, O. and Raskmark, P. (1997) Quality assurance for radiofrequency regional hyperthermia. Int J Hyperthermia, 13, pp. 169-185.
196. van Haaren, PM, Kok, HP, Vording, PJ Zum Vorde Sive, van Dijk, JD, Hulshof, MC, Fockens, P., van Lanschot, JJ and Crezee, J. (2006) Reliability of temperature and SAR measurements at oesophageal tumour locations. Int J Hyperthermia, 22, pp. 545-561.
197. van Rhoon, GC and Wust, P. (2005) Introduction: Non-invasive thermometry for thermotherapy. Int J Hyperthermia, 21, pp. 489-495.
198. Horsman, MR and Overgaard, J. (2007) Hyperthermia: A potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol), 19, pp. 418-426.
199. Norum, J., Olsen, JA, Wist, EA and Lonning, PE (2007) Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol, 46, pp. 153-164.
200. Starling, N., Tilden, D., White, J. and Cunningham, D. (2007) Cost-effectiveness analysis of cetuximab/irinotecan vs. active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer, 96, pp. 206-212.